This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.
McKesson (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit
by Zacks Equity Research
According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.
Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.
A Very Strong Q1 and 2021 Earnings Picture
by Sheraz Mian
This improving trend in estimate revisions accelerated over the last few months, as the chart below highlighting the evolution of 2021 Q1 earnings growth estimates shows...
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
McKesson (MCK) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.
Here's Why You Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on robust international performance and continued portfolio expansion.
Why Is McKesson (MCK) Down 5.1% Since Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo's (MASI) Rad-G with Temperature Receives CE Marking
by Zacks Equity Research
Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
The Zacks Analyst Blog Highlights: Facebook, Nike, Zoom Video, Micron Tech and McKesson Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Nike, Zoom Video, Micron Tech and McKesson Corp
Top Research Reports for Facebook, Nike & Zoom Video
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), NIKE, Inc. (NKE) and Zoom Video Communications, Inc. (ZM).
Thermo Fisher (TMO) Rides on Pharma & Biotech Amid Pandemic
by Zacks Equity Research
Customers in Thermo Fisher's (TMO) industrial and applied end markets get affected by business disruptions due to the pandemic.
Integra (IART) Arms Grow Sequentially Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
Bruker (BRKR) Rides on Product Launches Amid COVID-19 Woes
by Zacks Equity Research
Within Bruker's (BRKR) Nano Group Semiconductor metrology revenues have been steady with order rates improving as semi metrology equipment markets are witnessing a rebound.